This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J (JNJ) to Begin Q2 Earnings Season for Drug, Biotech Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex. In the MedTech segment, recovery in surgical procedures and new product launches are likely to have pushed sales growth.
Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants
by Zacks Equity Research
Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $67.05, marking a -0.49% move from the previous day.
Will Carelon Growth Aid Elevance Health's (ELV) Q2 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to reflect rising memberships in Medicare Advantage, Medicaid, Vision and Dental Administration businesses.
Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q2 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) second-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues, as well as the number of people served.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $64.86 in the latest trading session, marking a -0.51% move from the prior day.
Will High Medical Costs Affect UnitedHealth (UNH) Q2 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) second-quarter results are likely to reflect growth in memberships and expense levels.
Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study
by Zacks Equity Research
Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights BHP Group, AstraZeneca, The Boeing, Diageo and General Mills
by Zacks Equity Research
BHP Group, AstraZeneca, The Boeing, Diageo and General Mills are part of the Zacks top Analyst Blog.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $64.85 in the latest trading session, marking a -0.86% move from the prior day.
Top Analyst Reports for BHP Group, AstraZeneca & Boeing
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including BHP Group Limited (BHP), AstraZeneca PLC (AZN) and The Boeing Company (BA).
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine
by Zacks Equity Research
Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.
AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results
by Zacks Equity Research
While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $71.67 in the latest trading session, marking a -0.08% move from the prior day.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $71.73, moving -0.54% from the previous trading session.
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
by Zacks Equity Research
Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.
FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer
by Zacks Equity Research
Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing standard of care for treating HRR gene-mutated mCRPC.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $73.95, marking a -1.69% move from the previous day.
AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business
by Zacks Equity Research
AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $74.13, moving +0.38% from the previous trading session.